Prot #CA2097FL: A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+),

Project: Research project

Project Details

StatusActive
Effective start/end date2/5/21 → 2/5/26

Funding

  • Bristol-Myers Squibb Company ((OE) Prot #CA2097FL)